Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so familiar routine of Zoom meetings, Skype calls, and deadlines has predictably returned. To cope, yes, we are brewing cups of stimulation. Happily, our pantry is filled with a few new flavors, and today we are reaching for cinnamon mocha. Feel free to join us. Meanwhile, here are a few tidbits to help you get started. We hope that your day is productive and that you stay safe. So wear a mask. …

An obscure South Carolina company may be in line for millions of dollars in U.S. government funding to produce a coronavirus treatment after a former Republican senator with a financial stake in the business lobbied senior U.S. government officials, the Associated Press reports. Plasma Technologies received seed money to test a possible Covid-19-fighting blood plasma technology. As much as $65 million more could be on the way, a windfall for the company that operates out of the founder’s luxury condo.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.